TCM formula granule VBP brings challenge for company, but it also brings hope. There're breakthrough point of CAR-T's price decline. Gan & Lee has recovered from VBP, with further rebound ahead
What is covered in the Full Insight:
Performance Analysis of TCM Formula Granule Enterprises
Challenges and Progress in CAR-T Therapy
Overview of Gan & Lee Pharmaceuticals’ Core Insulin Business
Market Review
Risk Disclosure
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.